|
|
|
|
|
|
|
M T Wed Th F |
|
30 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
It’s my favorite time of year: We’re hosting our annual Women in Biopharma event next Tuesday, Oct. 6, at 11 a.m. ET. In addition to celebrating this year’s class of honorees, I’ll be joined by Yale University’s Carolyn Mazure, who founded one of the country’s first academic centers for women's health. We’ll discuss the current state of women’s health research and where the science should go next. You can register to watch here. |
|
|
|
Nicole DeFeudis |
Senior Reporter, Endpoints News
@Nicole_DeFeudis
|
|
|
|
|
|
|
by Zachary Brennan
|
The American Biotech Innovation Alliance took to Capitol Hill this week to tell members of Congress that the fight for US dominance in biopharma needs... | |
|
|
|
|
|
|
by Kevin Miller
|
A patient’s death is raising safety questions ahead of an upcoming readout for Bristol Myers Squibb’s lung disease candidate. Bristol Myers disclosed one case of... | |
|
|
|
|
|
|
|
|
by Elizabeth Cairns
|
MILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
MILAN— Eli Lilly said Tuesday that its triple agonist retatrutide helped patients with both obesity and type 2 diabetes lose up to 18.8% of... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
MILAN — Weight loss with Zealand Pharma and Roche’s amylin analog was regarded as disappointing when its Phase 2 obesity trial reported topline datain... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Sarepta, Rafael Holdings, Sagimet, Pyxis Oncology, Connect Biopharma, Asahi Kasei, Astrocyte Pharmaceuticals, GSK, Wave and Kailera. AbbVie unveils Phase 2 data for... | |
|
|
|
|
|
